DRKS00014829已完成2 期
Effects of Magnesium orotate in patients with heartfailure with decreased ejection fraction on NTproBNP - a prospective, monocentric, randomized, double blind Placebo-controlled cross-over study - MACH 2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Male or female patients = 18 years
- •2. Patients with chronic heart failure who have been treated continuously for at least 3 months according to current guidelines
- •3. NYHA Class II-IV
- •4. LVEF < 45%
- •5. NTproBNP >= 600 pg / ml (most recent value in the last 3 months)
- •6. Willingness to abstain from consuming alcohol during the study period
- •7. Existence of written consent
排除标准
- •1. LVEF = 45%
- •2. NTproBNP < 600 pg / ml
- •3. Known hypersensitivity to magnesium or any of the other ingredients
- •of the test medication
- •4. Currently decompensated heart failure
- •5. Severe renal impairment
- •6. GFR <30 ml / min / 1.73 m2
- •7. Acute coronary syndrome in the last 3 months before inclusion
- •8. Myasthenia gravis
- •9. Known AV block grade 2 or 3
- •10. Existing or planned pregnancy or women who breastfeed
- •11. Myocarditis, valvular cardiomyopathy, Tako-Tsubo cardiomyopathy, or peripartum cardiomyopathy
- •12. Patients who had an organ transplant
- •13. Patients who have a LVAD
- •14. Hb <8 g / dl
- •15. AST / ALT> 3 x ULN
- •16. Stroke / TIA in the last 3 months
- •17. Heart failure in the last 3 months
- •18. Cancer disease or treatment in the last 5 years
- •19. Tuberculosis, hepatitis, HIV infection or other serious viral diseases
- •20. Depressive illnesses with suicidal thoughts or suicide attempt (s) in the anamnesis
- •21. Severe mitral or aortic valve disease
- •22. Existence of diseases with a life expectancy <1 year
- •23. Any clinical finding which, in the opinion of the investigator, affects participation in the study
- •24. Dependency relationship with the sponsor or the study staff
- •25. Simultaneous participation in other clinical trials or registries
- •26. Ingestion of magnesium orotate in the past 12 months
- •27. Ingestion of other magnesium compounds in the last 4 weeks
- •28. Patients who are not expected to adhere to the guidelines in the study protocol (lack of compliance)
研究者
相似试验
尚未招募
不适用
Efficacy of magnesium in treatment of patients with myofascial trigger points in upper trapeziusCTRI/2022/01/039267Department of Physiotherapy and sports medicine Nanavati Super Speciality Hospital
尚未招募
3 期
Oral Magnesium Therapy in Periodic Limb Movement SyndromeIRCT20170128032249N2Tehran University of Medical Sciences28
尚未招募
Unknown
Investigating the effect of oral magnesium supplementation on cognitive function, fatigue, depression, anxiety of multiple sclerosis patientsMultiple sclerosisIRCT20220101053582N2Tehran University of Medical Sciences58
尚未招募
不适用
EFFECT OF MAGNESIUM SULPHATE IN REDUCING POST-OPERATIVE AGITATION AND PAIN AFTER NASAL SURGERIESCTRI/2023/01/048877MS Ramaiah Medical Collrge
尚未招募
2 期
Effects of magnesium along with exercises in treatment for patients with knee paiCTRI/2023/10/058599Dr Khadija Lokhandwala